Ok_老虎社区_美港股上老虎

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":609090418,"tweetId":"609090418","gmtCreate":1638204636134,"gmtModify":1638204636843,"author":{"id":3580117627003048,"idStr":"3580117627003048","authorId":3580117627003048,"authorIdStr":"3580117627003048","name":"FSYE","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":52,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Ok</p></body></html>","htmlText":"<html><head></head><body><p>Ok</p></body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/609090418","repostId":1137204965,"repostType":4,"repost":{"id":"1137204965","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638199520,"share":"https://www.laohu8.com/m/news/1137204965?lang=zh_CN&edition=full","pubTime":"2021-11-29 23:25","market":"us","language":"en","title":"NRx Pharmaceuticals stock surged 27% in morning trading<blockquote>NRx Pharmaceuticals 股价早盘飙升 27%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1137204965","media":"Tiger Newspress","summary":"NRx Pharmaceuticals stock surged 27% in morning trading after it identified significantly higher lik","content":"<p>NRx Pharmaceuticals stock surged 27% in morning trading&nbsp;after&nbsp;it&nbsp;identified significantly higher likelihood of surviving and recovering from Critical COVID-19 in ZYESAMI® (aviptadil) treated patients previously administered remdesivir.</p><p><blockquote>NRx Pharmaceuticals 股价在早盘交易中飙升 27%，此前该公司发现 ZYESAMI 从严重的 COVID-19 中生存和康复的可能性显着增加®（aviptadil）治疗既往接受瑞德西韦治疗的患者。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/50a474a64f50c3ff0cfc1f4f77930314\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> NRx Pharmaceuticals&nbsp;announced today that it has completed an analysis to identify clinical evidence that indicates a substantial improvement after treatment with ZYESAMI® (aviptadil) in patients with Critical COVID-19 and Respiratory Failure over existing therapies such as remdesivir. NRx asked Prof. David Schoenfeld, one of the world’s most widely published statisticians with unique expertise in life-threatening diseases of the lung to conduct the analysis.</p><p><blockquote>NRx Pharmaceuticals今天宣布，它已经完成了一项分析，以确定表明ZYESAMI治疗后显著改善的临床证据®（aviptadil）用于危重新冠肺炎和呼吸衰竭患者，优于现有疗法（如瑞德西韦）。NRx 请大卫-舍恩菲尔德教授（David Schoenfeld）进行分析，他是世界上发表论文最多的统计学家之一，在危及生命的肺部疾病方面拥有独特的专业知识。</blockquote></p><p> <ul>  <li>Analysis was conducted in the subgroup of ZYESAMI- and placebo-treated patients who were previously treated with remdesivir in the COVID-AIV trial representing approximately 70 percent of the study population</p><p><blockquote><ul><li>在COVID-AIV试验中先前接受瑞德西韦治疗的ZYESAMI和安慰剂治疗的患者亚组中进行了分析，约占研究人群的70%</li></ul></blockquote></p><p></li>  <li>Analysis was conducted in response to US Food and Drug Administration (FDA) request for additional clinical data on effect of ZYESAMI compared to currently-approved therapy including remdesivir</p><p><blockquote><li>分析是应美国食品药品监督管理局（FDA）要求提供关于ZYESAMI与包括瑞德西韦在内的当前批准治疗相比的疗效的额外临床数据而进行的</li></blockquote></p><p></li>  <li>NRx to submit new analysis and safety data to the FDA in support of Emergency Use Authorization and Breakthrough Therapy Designation Requests</p><p><blockquote><li>NRx将向FDA提交新的分析和安全性数据，以支持紧急使用授权和突破性疗法指定请求</li></blockquote></p><p></li>  <li>US National Institutes of Health-sponsored trial to compare effects of ZYESAMI and remdesivir individually and in combination continues to enroll patients</p><p><blockquote><li>美国国立卫生研究院赞助的比较ZYESAMI和remdesivir单独和联合治疗效果的试验继续招募患者</li></blockquote></p><p></li> </ul> <ul></ul></p><p><blockquote><ul></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NRx Pharmaceuticals stock surged 27% in morning trading<blockquote>NRx Pharmaceuticals 股价早盘飙升 27%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNRx Pharmaceuticals stock surged 27% in morning trading<blockquote>NRx Pharmaceuticals 股价早盘飙升 27%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 23:25</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>NRx Pharmaceuticals stock surged 27% in morning trading&nbsp;after&nbsp;it&nbsp;identified significantly higher likelihood of surviving and recovering from Critical COVID-19 in ZYESAMI® (aviptadil) treated patients previously administered remdesivir.</p><p><blockquote>NRx Pharmaceuticals 股价在早盘交易中飙升 27%，此前该公司发现 ZYESAMI 从严重的 COVID-19 中生存和康复的可能性显着增加®（aviptadil）治疗既往接受瑞德西韦治疗的患者。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/50a474a64f50c3ff0cfc1f4f77930314\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> NRx Pharmaceuticals&nbsp;announced today that it has completed an analysis to identify clinical evidence that indicates a substantial improvement after treatment with ZYESAMI® (aviptadil) in patients with Critical COVID-19 and Respiratory Failure over existing therapies such as remdesivir. NRx asked Prof. David Schoenfeld, one of the world’s most widely published statisticians with unique expertise in life-threatening diseases of the lung to conduct the analysis.</p><p><blockquote>NRx Pharmaceuticals今天宣布，它已经完成了一项分析，以确定表明ZYESAMI治疗后显著改善的临床证据®（aviptadil）用于危重新冠肺炎和呼吸衰竭患者，优于现有疗法（如瑞德西韦）。NRx 请大卫-舍恩菲尔德教授（David Schoenfeld）进行分析，他是世界上发表论文最多的统计学家之一，在危及生命的肺部疾病方面拥有独特的专业知识。</blockquote></p><p> <ul>  <li>Analysis was conducted in the subgroup of ZYESAMI- and placebo-treated patients who were previously treated with remdesivir in the COVID-AIV trial representing approximately 70 percent of the study population</p><p><blockquote><ul><li>在COVID-AIV试验中先前接受瑞德西韦治疗的ZYESAMI和安慰剂治疗的患者亚组中进行了分析，约占研究人群的70%</li></ul></blockquote></p><p></li>  <li>Analysis was conducted in response to US Food and Drug Administration (FDA) request for additional clinical data on effect of ZYESAMI compared to currently-approved therapy including remdesivir</p><p><blockquote><li>分析是应美国食品药品监督管理局（FDA）要求提供关于ZYESAMI与包括瑞德西韦在内的当前批准治疗相比的疗效的额外临床数据而进行的</li></blockquote></p><p></li>  <li>NRx to submit new analysis and safety data to the FDA in support of Emergency Use Authorization and Breakthrough Therapy Designation Requests</p><p><blockquote><li>NRx将向FDA提交新的分析和安全性数据，以支持紧急使用授权和突破性疗法指定请求</li></blockquote></p><p></li>  <li>US National Institutes of Health-sponsored trial to compare effects of ZYESAMI and remdesivir individually and in combination continues to enroll patients</p><p><blockquote><li>美国国立卫生研究院赞助的比较ZYESAMI和remdesivir单独和联合治疗效果的试验继续招募患者</li></blockquote></p><p></li> </ul> <ul></ul></p><p><blockquote><ul></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NRXP":"NRX Pharmaceuticals Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137204965","content_text":"NRx Pharmaceuticals stock surged 27% in morning trading after it identified significantly higher likelihood of surviving and recovering from Critical COVID-19 in ZYESAMI® (aviptadil) treated patients previously administered remdesivir.\n\nNRx Pharmaceuticals announced today that it has completed an analysis to identify clinical evidence that indicates a substantial improvement after treatment with ZYESAMI® (aviptadil) in patients with Critical COVID-19 and Respiratory Failure over existing therapies such as remdesivir. NRx asked Prof. David Schoenfeld, one of the world’s most widely published statisticians with unique expertise in life-threatening diseases of the lung to conduct the analysis.\n\nAnalysis was conducted in the subgroup of ZYESAMI- and placebo-treated patients who were previously treated with remdesivir in the COVID-AIV trial representing approximately 70 percent of the study population\nAnalysis was conducted in response to US Food and Drug Administration (FDA) request for additional clinical data on effect of ZYESAMI compared to currently-approved therapy including remdesivir\nNRx to submit new analysis and safety data to the FDA in support of Emergency Use Authorization and Breakthrough Therapy Designation Requests\nUS National Institutes of Health-sponsored trial to compare effects of ZYESAMI and remdesivir individually and in combination continues to enroll patients","news_type":1,"symbols_score_info":{"NRXP":0.9}},"isVote":1,"tweetType":1,"viewCount":1100,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/609090418"}